Rezdiffra Signals New Beginnings for NASH Drug Development

Ajouter une nouvelle offre d'emploi Autre

2025-07-09 09:59:05

The therapeutic landscape for non-alcoholic steatohepatitis (NASH) has undergone a dramatic transformation with Madrigal Pharmaceuticals' introduction of Rezdiffra (resmetirom), marking an unprecedented milestone in hepatic medicine. This revolutionary medication stands as the inaugural FDA-approved treatment specifically targeting NASH with fibrosis, fundamentally changing how clinicians...

0 Commentaires 0 Parts 100 Vue 0 Aperçu